Today: 1 May 2026
Shell share price in focus after Kazakhstan investment pause and PwC audit switch
8 February 2026
2 mins read

Shell share price in focus after Kazakhstan investment pause and PwC audit switch

London, Feb 8, 2026, 07:59 GMT — The market is shut.

Shell Plc is hitting pause on fresh Kazakhstan investments while legal battles with the state drag out, CEO Wael Sawan told analysts. “We will hold until we have better line of sight to where things end up,” he said. Kazakhstan is pursuing $13 billion and $3.5 billion in contested costs tied to the Kashagan and Karachaganak oilfields. One arbitration result could land between $2 billion and $4 billion, according to sources. Reuters

Shell’s shares in London (SHEL.L) ended Friday at 2,774.5 pence, ticking up 5 pence, or 0.18%. Markets are closed for now, leaving investors to weigh legal uncertainties against reliable shareholder payouts heading into Monday.

Shell’s latest quarter didn’t meet profit forecasts, but the company stuck with its $3.5 billion buyback and bumped its dividend up 4% to $0.372 a share. Chief Financial Officer Sinead Gorman described the payout range as “sacrosanct.” With oil and gas prices coming off the boil, traders are gauging whether buybacks in the sector will stay intact. Exxon has said it’ll keep its buyback unchanged this year; Equinor has trimmed its own program. Reuters

Shell on Friday named PricewaterhouseCoopers as its next auditor starting in 2027, following a tender that will see PwC take over from EY. In December, Britain’s Financial Reporting Council launched a probe into EY’s audit of Shell’s 2024 results. Shell said it will revise its 2023 and 2024 annual reports, but the actual financial statements aren’t affected. The company added PwC’s appointment is headed to a shareholder vote at the 2027 annual meeting. EY will stick around for audits through 2026, pending approval at the 2026 AGM.

Shell disclosed it bought back 1,637,748 shares for cancellation on Feb. 6, executing purchases across multiple venues as outlined in the buyback plan announced earlier in the week. Trading decisions for the programme are being handled independently by Morgan Stanley & Co International through May 1, according to the company.

Shell’s LNG operations are drawing scrutiny. Atlantic LNG in Trinidad and Tobago is set to take Train 4 offline starting May 4 for what could be 50 days of maintenance, according to people with knowledge of the schedule—a pause that might cut output by over 600,000 metric tons, using last year’s numbers. Shell and BP each hold a 45% stake in Atlantic LNG, which, per company figures, accounts for about 10% of Shell’s LNG production next year.

Oil finished Friday in positive territory, giving energy stocks a lift heading into the week. Brent crude wrapped up at $68.05 per barrel, a gain of 0.74%. Traders cited renewed U.S.-Iran tensions after Oman-mediated talks failed to bridge differences. WTI ticked up too, closing at $63.55, up 0.41%.

The risks aren’t hard to see. Kazakhstan’s legal wrangling could widen or run up a bigger bill than anticipated. The government has already hinted at a fresh, possibly heavier, claim over Kashagan. Even as companies maintain the figures hold, governance headaches—think audit rotation or updated filings—can stick around.

Shell’s fortunes are still tied to the volatile crude-and-gas cycle. If oil prices tumble on demand jitters, sentiment could sour in a hurry—and questions about how secure those hefty buybacks really are may get louder. For the moment, investors are dealing with the same old trade-off: hefty cash returns, countered by a dose of project and political risk.

Next up: Shell’s dividend schedule. Ordinary shares go ex-dividend Feb. 19, while holders of U.S. ADRs face a Feb. 20 cutoff. Investors buying in after those dates miss the next payout, which lands March 30.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:12 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
iFAST stock slides into a big week: earnings date, Singapore budget and what traders watch next
Previous Story

iFAST stock slides into a big week: earnings date, Singapore budget and what traders watch next

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026
Next Story

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026

Go toTop